Class
Selective MAO-B inhibitor
Mechanism
Inhibits monoamine oxidase B, increasing striatal dopamine levels
FDA-Approved Use
Parkinson’s disease (PD)
Off-Label Use
Depression in PD, cognitive slowing, apathy in PD
Formulation
Oral tablets
Titration
0.5–1 mg p.o. daily
Dose Range
0.5–1 mg/day
Kinetics
Hepatic metabolism (CYP1A2); half-life ~3 hours
Common AEs
Headache, arthralgia, indigestion
Serious/Rare AEs
Serotonin syndrome risk with serotonergic agents
Monitoring
Monitor for serotonin syndrome if combined with antidepressants
Black Box Warning
None
Considerations
Generally well tolerated in Parkinson’s disease; caution with SSRIs/SNRIs; monitor mood symptoms in depression treatment.